CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein

[1]  H. Wilton-Clark,et al.  Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy , 2023, Pharmaceutics.

[2]  Hui Yang,et al.  CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives , 2022, Cells.

[3]  M. Matsuo,et al.  Human Dystrophin Dp71ab Enhances the Proliferation of Myoblasts Across Species But Not Human Nonmyoblast Cells , 2022, Frontiers in Cell and Developmental Biology.

[4]  T. Yokota,et al.  CRISPR Therapeutics for Duchenne Muscular Dystrophy , 2022, International journal of molecular sciences.

[5]  V. Soldatov,et al.  Therapeutic potential of highly functional codon-optimized microutrophin for muscle-specific expression , 2022, Scientific Reports.

[6]  K. Lim,et al.  Natural History of a Mouse Model Overexpressing the Dp71 Dystrophin Isoform , 2021, International journal of molecular sciences.

[7]  A. Wagers,et al.  Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species , 2021, Cell.

[8]  William H. Majoros,et al.  Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  P. Clemens,et al.  Exon-Skipping in Duchenne Muscular Dystrophy , 2021, Journal of neuromuscular diseases.

[10]  E. Olson.  Toward the correction of muscular dystrophy by gene editing , 2021, Proceedings of the National Academy of Sciences.

[11]  Eunyoung Choi,et al.  CRISPR technologies for the treatment of Duchenne muscular dystrophy , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  E. Olson,et al.  Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing , 2021, Science Advances.

[13]  E. Hyatt,et al.  Targeted genome editing in vivo corrects a Dmd duplication restoring wild‐type dystrophin expression , 2021, EMBO molecular medicine.

[14]  E. Mercuri,et al.  Duchenne muscular dystrophy , 2021, Nature Reviews Disease Primers.

[15]  E. Kmiec,et al.  Deconvolution of Complex DNA Repair (DECODR): Establishing a Novel Deconvolution Algorithm for Comprehensive Analysis of CRISPR-Edited Sanger Sequencing Data , 2021, The CRISPR journal.

[16]  H. Nishio,et al.  Dystrophin Dp71ab is monoclonally expressed in human satellite cells and enhances proliferation of myoblast cells , 2020, Scientific Reports.

[17]  M. Matsuo,et al.  Pathological evaluation of rats carrying in-frame mutations in the dystrophin gene: a new model of Becker muscular dystrophy , 2020, Disease Models & Mechanisms.

[18]  S. Orlov,et al.  In vitro assay for the efficacy assessment of AAV vectors expressing microdystrophin. , 2020, Experimental cell research.

[19]  R. Weiss,et al.  X-linked muscular dystrophy in a Labrador Retriever strain: phenotypic and molecular characterisation , 2020, Skeletal Muscle.

[20]  E. Olson,et al.  Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system , 2020, Science Advances.

[21]  E. Wolf,et al.  Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy , 2020, Nature Medicine.

[22]  K. Anthony,et al.  Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy , 2019, Molecular Neurobiology.

[23]  Gregory J Jenkins,et al.  An improved method for studying mouse diaphragm function , 2019, Scientific Reports.

[24]  Monya Baker,et al.  Reporting animal research: Explanation and Elaboration for the ARRIVE guidelines 2019 , 2019, bioRxiv.

[25]  V. Buchman,et al.  CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene , 2019, Disease Models & Mechanisms.

[26]  Xinghui Wang,et al.  Identification of suitable reference genes for gene expression studies in rat skeletal muscle following sciatic nerve crush injury , 2019, Molecular medicine reports.

[27]  E. Olson,et al.  CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells , 2019, Science Advances.

[28]  H. Nishio,et al.  Identification of the shortest splice variant of Dp71, together with five known variants, in glioblastoma cells. , 2019, Biochemical and biophysical research communications.

[29]  Charles A. Gersbach,et al.  Long-term Evaluation of AAV-CRISPR Genome Editing for Duchenne Muscular Dystrophy , 2018, Nature Medicine.

[30]  K. Davies,et al.  Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2/mdx Mice , 2018, Molecular therapy. Methods & clinical development.

[31]  John M. Shelton,et al.  Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy , 2018, Science.

[32]  S. Vassilieva,et al.  DMD TREATMENT: ANIMAL MODELS P.203Exons 6 and 7 skipping test on new murine model of Duchenne muscular dystrophy , 2018, Neuromuscular Disorders.

[33]  J. Rousseau,et al.  CRISPR-induced deletion with SaCas9 restores dystrophin expression in dystrophic models in vitro and in vivo , 2018, bioRxiv.

[34]  H. Nishio,et al.  Detection of Dystrophin Dp71 in Human Skeletal Muscle Using an Automated Capillary Western Assay System , 2018, International journal of molecular sciences.

[35]  R. Maruyama,et al.  Skipping Multiple Exons to Treat DMD—Promises and Challenges , 2018, Biomedicines.

[36]  Malte Tiburcy,et al.  Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing , 2018, Science Advances.

[37]  G. Ronzitti,et al.  Emerging Issues in AAV-Mediated In Vivo Gene Therapy , 2017, Molecular therapy. Methods & clinical development.

[38]  K. Itoh,et al.  Dp71 is regulated by phosphorylation and ubiquitin-proteasome system in neuronal cells. , 2017, Biochemical and biophysical research communications.

[39]  M. Reinders,et al.  Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy , 2017, Scientific Reports.

[40]  Malte Tiburcy,et al.  Functional correction of dystrophin actin binding domain mutations by genome editing. , 2017, JCI insight.

[41]  A. Nakamura,et al.  Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy , 2017, Proceedings of the National Academy of Sciences.

[42]  E. Olson,et al.  Publication : CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice , 2018 .

[43]  Jerry C. Hu,et al.  A Modified Hydroxyproline Assay Based on Hydrochloric Acid in Ehrlich's Solution Accurately Measures Tissue Collagen Content. , 2017, Tissue engineering. Part C, Methods.

[44]  R. David Hawkins,et al.  Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy , 2017, Nature Communications.

[45]  Kornel Labun,et al.  CHOPCHOP v2: a web tool for the next generation of CRISPR genome engineering , 2016, Nucleic Acids Res..

[46]  A. Nakamura,et al.  Deletion of exons 3−9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy , 2016, Journal of Human Genetics.

[47]  J. Ervasti,et al.  Disease-proportional proteasomal degradation of missense dystrophins , 2015, Proceedings of the National Academy of Sciences.

[48]  C. M. Nolan,et al.  Muscular dystrophy in the Japanese Spitz: an inversion disrupts the DMD and RPGR genes. , 2015, Animal genetics.

[49]  Christophe Béroud,et al.  The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations , 2015, Human mutation.

[50]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[51]  William H. Majoros,et al.  Multiplex CRISPR/Cas9-Based Genome Editing for Correction of Dystrophin Mutations that Cause Duchenne Muscular Dystrophy , 2015, Nature Communications.

[52]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[53]  Annemieke Aartsma-Rus,et al.  Assessing functional performance in the mdx mouse model. , 2014, Journal of visualized experiments : JoVE.

[54]  G. Gao,et al.  The potential of adeno-associated viral vectors for gene delivery to muscle tissue , 2014, Expert opinion on drug delivery.

[55]  R. Deacon.  Measuring the Strength of Mice , 2013, Journal of visualized experiments : JoVE.

[56]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[57]  A. Nakamura,et al.  In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  S. Singh,et al.  Missense mutations in dystrophin that trigger muscular dystrophy decrease protein stability and lead to cross-β aggregates , 2010, Proceedings of the National Academy of Sciences.

[59]  C. Stefanski,et al.  Excessive collagen accumulation in dystrophic (mdx) respiratory musculature is independent of enhanced activation of the NF-κB pathway , 2010, Journal of the Neurological Sciences.

[60]  P. Morcos,et al.  Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. , 2008, BioTechniques.

[61]  Polina Golland,et al.  CellProfiler Analyst: data exploration and analysis software for complex image-based screens , 2008, BMC Bioinformatics.

[62]  A. Nakamura,et al.  Selective Vacuolar Degeneration in Dystrophin-Deficient Canine Purkinje Fibers Despite Preservation of Dystrophin-Associated Proteins With Overexpression of Dp71 , 2008, Circulation.

[63]  D. Duan,et al.  Prevention of Dystrophin-Deficient Cardiomyopathy in Twenty-One-Month-Old Carrier Mice by Mosaic Dystrophin Expression or Complementary Dystrophin/Utrophin Expression , 2008, Circulation research.

[64]  J. Chamberlain,et al.  Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. , 2007, Human molecular genetics.

[65]  G. van Ommen,et al.  Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame rule , 2006, Muscle & nerve.

[66]  A. Rabinowitz,et al.  Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology , 2006, Nature Medicine.

[67]  H. Jockusch,et al.  Acute pathophysiological effects of muscle-expressed Dp71 transgene on normal and dystrophic mouse muscle. , 2003, Journal of applied physiology.

[68]  A. Meshorer,et al.  Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle , 2002, Neuromuscular Disorders.

[69]  F. Baas,et al.  Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. , 2001, Human molecular genetics.

[70]  P. Ray,et al.  Alternative splicing regulates the nuclear or cytoplasmic localization of dystrophin Dp71 , 2000, FEBS letters.

[71]  Z. Levy,et al.  A 71-kilodalton protein is a major product of the Duchenne muscular dystrophy gene in brain and other nonmuscle tissues. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[72]  M. Korostyński,et al.  Full-length dystrophin is expressed across human tissues and DMD downregulation commonly occurring in tumours coincides with Duchenne-like molecular alterations , 2022 .

[73]  L. Fiette,et al.  Tissue Sampling and Processing for Histopathology Evaluation. , 2017, Methods in molecular biology.

[74]  T. Weber,et al.  Production and Characterization of Vectors Based on the Cardiotropic AAV Serotype 9. , 2017, Methods in molecular biology.

[75]  G. Dickson,et al.  Gene therapy for Duchenne muscular dystrophy , 2012 .